ABSTRACT
· AIM:To investigate the clinical effect of Ranibizumab combined with photodynamic therapy (PDT) for wet type age-related macular degeneration (wAMD) and the effect on the serum neovascularization factors.· METHODS:Totally 68 cases (68 eyes) of wAMD patients treated with PDT in our hospital from January 2014 to June 2016 were analyzed retrospectively.Among them,34 patients were treated by photodynamic therapy (control group) and 34 patients were treated by combination of photodynamic therapy and ranibizumab (treatment group).Comparison of BCVA,mean retinal thickness and central macular thickness (CMT) and serum neovascularization regulatory factors before and after treatment were taken between the two groups.· RESULTS:Before treatment,there was no significant difference on the BCVA,the average retinal thickness and the CMT value between the two groups (P＞0.05).At 3,6 and 12mo after treatment,the BCVA,average retinal thickness and CMT in both groups were significantly lower than those before treatment (P＜0.05).At 3,6 and 12mo after treatment,the BCVA,the average retinal thickness and the CMT value of the patients in the treatment group were significantly lower than those in the control group (P＜0.05).There was no significant difference of vascular endothelial growth factor (VEGF),platelet derived growth factor (PDGF),matrix metallo-proteinase inhibitor (TIMP)-1 and endostatin (ES) between the two groups before treatment (P＞ 0.05).Three months after treatment,VEGF,PDGF and ES in both groups were significantly lower than those before treatment (P＜0.05).Three months after treatment,the levels of VEGF,PDGF and ES in the treatment group were significantly lower than those in the control group (P＜0.05).· CONCLUSION:The wAMD patients treated with ranibizumab combined with photodynamic therapy can achieve a more significant clinical effect,and more effectively reduce the level of serum neovascularization regulators.
ABSTRACT
@#AIM:To investigate the effect of combination therapy with Ranibizumab and photodynamic therapy in the treatment of age-related macular degeneration.<p>METHODS: Totally 78 cases(86 eyes)with age-related macular degeneration in our hospital from January 2012 to December 2015 were selected as the subjects. The patients were randomly divided into two groups, 39 cases(42 eyes)were treated by combination as the combination group and 39 cases(44 eyes)as the control group(only treated with ranibizumab). The changes of visual acuity and choroidal neovascularization(CNV)leakage were compared between the two groups before and after treatment. <p>RESULTS: After treatment for 6 and 12wk, the best corrected visual acuity(BCVA)value of the combined group was higher than that of the control group, the difference was statistically significant(<i>P</i><0.05); the central retinal thickness(CRT)values of the patients in the combined group were lower than those in the control group, the difference was statistically significant(<i>P</i><0.05). After 12wk of treatment, the total effective rate for CNV leakage in the combined group was 90% compared with that of the control group(82%), there was no significant difference(<i>P</i>>0.05). <p>CONCLUSION: The efficacy of the combination therapy is good for CNV leakage, visual acuity and CRT in patients with age-related macular degeneration.